Sugi Predict

Sugi Predict / Compounds / SCHEMBL5152864

SCHEMBL5152864

SCHEMBL5152864

C[C@@H]1CC[C@H](C(=O)O)N1C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.47
▸ CHRM1 P11229 1/20 0.47
▸ CHRM3 P20309 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.40
▸ ACE P12821 1/20 0.40
▸ PREP P48147 4/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ HPGD P15428 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ GPR119 Q8TDV5 1/20 0.35
▸ ELANE P08246 1/20 0.35
▸ USP2 O75604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL646565 1.00 CHRM2 (0.47) CHRM2CHRM1CHRM3HSD17B10ACE
SCHEMBL6567834 1.00 CHRM2 (0.47) CHRM2CHRM1CHRM3HSD17B10ACE
SCHEMBL29050069 1.00 CHRM2 (0.47) CHRM2CHRM1CHRM3HSD17B10ACE
SCHEMBL627476 1.00 CHRM2 (0.47) CHRM2CHRM1CHRM3HSD17B10ACE
SCHEMBL192488 1.00 CHRM2 (0.47) CHRM2CHRM1CHRM3HSD17B10ACE
SCHEMBL20348248 1.00 CHRM2 (0.47) CHRM2CHRM1CHRM3HSD17B10ACE
SCHEMBL1294140 1.00 CHRM2 (0.47) CHRM2CHRM1CHRM3HSD17B10ACE
SCHEMBL192489 1.00 CHRM2 (0.47) CHRM2CHRM1CHRM3HSD17B10ACE
SCHEMBL5955704 0.90 ACE (0.51) CHRM2CHRM1CHRM3HSD17B10ACE
SCHEMBL18018402 0.90 ACE (0.51) CHRM2CHRM1CHRM3HSD17B10ACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026087442-A1 AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2026-04-30 — — WO disclosed
US-20250368641-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORP (US) 2025-12-04 — — US disclosed
EP-4656201-A2 RAS INHIBITORS Revolution Medicines, Inc. (US) 2025-12-03 — — EP disclosed
US-12378243-B2 Quinoline compounds as inhibitors of KRAS INCYTE CORPORATION (US) 2025-08-05 — — US disclosed
US-20250195521-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS Revolution Medicines, Inc. 2025-06-19 — — US disclosed
US-20250136582-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF 1200 PHARMA LLC (US) 2025-05-01 — — US disclosed
US-20250051306-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-02-13 — — US disclosed
CN-119156383-A Selective KRAS G12C inhibitors and uses thereof 1200药业有限责任公司 2024-12-17 — — CN disclosed
US-20240368152-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORPORATION 2024-11-07 — — US disclosed
EP-4415824-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS Incyte Corporation (US) 2024-08-21 — — EP disclosed
CN-112679407-B Preparation method of chiral 5-substituted proline compound 南京桦冠生物技术有限公司 2021-06-04 — — CN disclosed
US-20210130326-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2021-05-06 — — US disclosed
US-20210130326-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2021-05-06 — — US disclosed
CN-112679407-A Preparation method of chiral 5-substituted proline compound 南京桦冠生物技术有限公司 2021-04-20 — — CN disclosed
US-20070054909-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 — — US disclosed
US-7179819-B2 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 — — US disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 — — US disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 — — US disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 — — US disclosed
CN-1391473-A VLA-4 inhibitor compounds DAIICHI SEIYAKU CO (JP) 2003-01-15 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136582-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF KRAS, NRAS, HRAS CHRM2 4881/4885CHRM1 4873/4885CHRM3 4884/4885
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 CHRM2 2236/4885CHRM1 1416/4885CHRM3 2033/4885
US-20070054909-A1 VLA-4 inhibitor compounds VCAM1, ITGB4, ICAM1 CHRM2 1982/4885CHRM1 1248/4885CHRM3 1817/4885
US-20250051306-A1 RAS INHIBITORS KRAS, NRAS, HRAS CHRM2 4885/4885CHRM1 4884/4885CHRM3 4874/4885
US-20250195521-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS SOS1, PPM1D, PTPN1 CHRM2 4876/4885CHRM1 4864/4885CHRM3 4877/4885
US-12378243-B2 Quinoline compounds as inhibitors of KRAS KRAS, NRAS, HRAS CHRM2 4782/4885CHRM1 4747/4885CHRM3 4777/4885
US-20240368152-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS KRAS, NRAS, HRAS CHRM2 4782/4885CHRM1 4747/4885CHRM3 4777/4885
US-20210130326-A1 RAS INHIBITORS KRAS, NRAS, HRAS CHRM2 4885/4885CHRM1 4884/4885CHRM3 4874/4885
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 CHRM2 2195/4885CHRM1 1403/4885CHRM3 2018/4885
US-20250368641-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS KRAS, NRAS, HRAS CHRM2 4782/4885CHRM1 4747/4885CHRM3 4777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.